These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 31314738)
21. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104 [TBL] [Abstract][Full Text] [Related]
22. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Vekeman F; Bookhart BK; White J; McKenzie RS; Duh MS; Piech CT; Lefebvre P Transfusion; 2009 May; 49(5):895-902. PubMed ID: 19175548 [TBL] [Abstract][Full Text] [Related]
23. [Questionnaire-based survey on chemotherapy-induced anemia]. Tanaka A Gan To Kagaku Ryoho; 2014 Apr; 41(4):421-5. PubMed ID: 24743357 [TBL] [Abstract][Full Text] [Related]
24. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Ross SD; Allen IE; Henry DH; Seaman C; Sercus B; Goodnough LT Clin Ther; 2006 Jun; 28(6):801-31. PubMed ID: 16860166 [TBL] [Abstract][Full Text] [Related]
25. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304 [TBL] [Abstract][Full Text] [Related]
26. Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL. Pirker R; Hedenus M; Vansteenkiste J; Hernandez E; Belton L; Terwey JH Clin Ther; 2016 Jan; 38(1):122-135.e6. PubMed ID: 26730453 [TBL] [Abstract][Full Text] [Related]
27. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review. Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152 [TBL] [Abstract][Full Text] [Related]
28. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study. Tsuboi M; Ezaki K; Tobinai K; Ohashi Y; Saijo N Jpn J Clin Oncol; 2009 Mar; 39(3):163-8. PubMed ID: 19164318 [TBL] [Abstract][Full Text] [Related]
29. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions. Hess G; Nordyke RJ; Hill J; Hulnick S Am J Hematol; 2010 Nov; 85(11):838-43. PubMed ID: 20976794 [TBL] [Abstract][Full Text] [Related]
30. [Treatment of chemotherapy-induced anemia]. Kadokura G; Katsumata N Gan To Kagaku Ryoho; 2014 Apr; 41(4):416-20. PubMed ID: 24743356 [TBL] [Abstract][Full Text] [Related]
31. Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review. Henry DH; Langer CJ; McKenzie RS; Piech CT; Senbetta M; Schulman KL; Stepanski EJ Support Care Cancer; 2012 Sep; 20(9):2089-96. PubMed ID: 22160485 [TBL] [Abstract][Full Text] [Related]
32. The addition of oral iron improves chemotherapy-induced anemia in patients receiving erythropoiesis-stimulating agents. Tan J; Du S; Zang X; Ding K; Ginzburg Y; Chen H Int J Cancer; 2022 Nov; 151(9):1555-1564. PubMed ID: 35639027 [TBL] [Abstract][Full Text] [Related]
33. Chemotherapy-induced anemia in adults: incidence and treatment. Groopman JE; Itri LM J Natl Cancer Inst; 1999 Oct; 91(19):1616-34. PubMed ID: 10511589 [TBL] [Abstract][Full Text] [Related]
34. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Wu Y; Aravind S; Ranganathan G; Martin A; Nalysnyk L Clin Ther; 2009; 31 Pt 2():2416-32. PubMed ID: 20110050 [TBL] [Abstract][Full Text] [Related]
35. Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients. Gilreath JA; Sageser DS; Jorgenson JA; Rodgers GM J Natl Compr Canc Netw; 2008 Jul; 6(6):577-84. PubMed ID: 18597711 [TBL] [Abstract][Full Text] [Related]
36. Hemoglobin decline in chemotherapy patients prior to and after policy changes affecting use of erythropoiesis-stimulating agents: 2006-2009. Hill JW; Cong Z; Hess G; McGarvey N; Nordyke RJ J Int Med Res; 2012; 40(4):1532-45. PubMed ID: 22971506 [TBL] [Abstract][Full Text] [Related]
37. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748 [TBL] [Abstract][Full Text] [Related]
38. Experimental and investigational therapies for chemotherapy-induced anemia. Testa U; Castelli G; Elvira P Expert Opin Investig Drugs; 2015; 24(11):1433-45. PubMed ID: 26359222 [TBL] [Abstract][Full Text] [Related]
39. Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia. Muller RJ; Baribeault D Am J Health Syst Pharm; 2007 Dec; 64(24):2547-56. PubMed ID: 18056942 [TBL] [Abstract][Full Text] [Related]
40. Impact of erythropoiesis-stimulating agent prescribing at an Asian cancer center, after release of safety advisories. Chan Q; Chan A J Oncol Pharm Pract; 2011 Dec; 17(4):350-9. PubMed ID: 20659968 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]